Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. Peng DH, et al. Among authors: wistuba ii. Sci Transl Med. 2019 Mar 13;11(483):eaaq1238. doi: 10.1126/scitranslmed.aaq1238. Sci Transl Med. 2019. PMID: 30867319 Free PMC article.
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. Fujimoto N, et al. Among authors: wistuba ii. Cancer Res. 2005 Dec 15;65(24):11478-85. doi: 10.1158/0008-5472.CAN-05-1977. Cancer Res. 2005. PMID: 16357156
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Byers LA, et al. Among authors: wistuba ii. Mol Cancer Ther. 2010 Jun;9(6):1755-63. doi: 10.1158/1535-7163.MCT-09-1047. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530716 Free PMC article.
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Cai D, et al. Cancer Res. 2010 Aug 15;70(16):6477-85. doi: 10.1158/0008-5472.CAN-10-0005. Epub 2010 Jul 27. Cancer Res. 2010. PMID: 20663904 Free PMC article.
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Johnson FM, et al. J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855820 Free PMC article. Clinical Trial.
725 results